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A B S T R A C T
Several  new aspects  of  radioimmunotargeting for neoplast ic lesions
are reviewed in this paper. These include the use of single domain
antibody, oncogene-coded protein and other intracellular targets so as
to obtain pancarcinoma reactivi ty,  newer methods of l inking %Tc  to
antibodies for radioimmunoscintigraphy. The selection of candidate
radionuclides for  radioimmunotherapy,  part icularly the possible use of
radiosilver and radiogold, and the strategies of enhanced tumour
targeting were also reviewed.
1. INTRODUCTION
Over the last ten years there has-been an explosion of activities in the field of
radioimmunotargeting. Ehrlich’s concept of ‘magic bullet’ selectively targeting noxious
cells without harming the healthy host cells was achieved in the case of most bacteria
after the epoch-making red dye-prontosil. Similar selective immunotargeting of cancer
cells now appears to be possible with the use of the fine specificity of the antigen-
antibody recognition. The advent of hybridoma technology for generating pure
monoclonal antibodies in gram quantities, the recognition of the repertoire of
tumour-associated antigen and the availability of DNA recombinant technology were
some of the important links in the chain that promises to contribute to the successful
immunotargeting. The amount of interest generated in this field can be gauged by
the fact that at least five major companies have mounted research efforts in the
development of radioimmunotherapy, and one of these was proclaiming the slogan:
‘Monoclonal Antibodies-The Vision of the Future’, at the Society of Nuclear
Medicine Meeting at Washington in June 1990.
The promises and problems in radioimmunotargeting have been reviewed over
the last five years by several workers and our own group had reviewed the
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state-of-the-art from 1988 onward&*. The present paper will focus on some newer
advances in the field of radioimmunotargeting.
2. SINGLE DOMAIN ANTIBODIES
The conventional dogma that antigen recognition and binding are dependent on
the properties of the terminal domains of both light and heavy chains has now been
challenged by the report from Cambridge3 that a single domain of heavy chain is
sufficient to ensure specific binding. These single domains are produced in an ingenious
manner combining the two frontier areas of hybridoma technology and genetic
engineering. The hybridomas are first produced in the usual manner4.  The DNA
sequences of these hybridomas are then cloned, followed by amplification by
polymerase chain reaction and the use of transfection to place these DNA fragments
by plasmids  into E coli bacteria‘. The bacteria then express and secrete the sipgle
heavy chain domains of desired specificity. It is much easier to maintain bacterial
cultures as compared to tissue cultures of hybridoma cells. Further, these single domain
antibodies may avoid the hypersensitivity-HAMA  (human antimouse antibody)
reaction, enhancing stability of. the radionuclide-chelate-antibody linkage. It is also
expected that these single domain antibodies will be easier to couple without distortion
of antigen combining sites. The affinity of single domain antibodies is lower than that
of the conventional monoclonal antibodies but it may be possible to overcome this
by using larger quantities.
3. ONCOGENES AS TARGETS
As far back as 1982, Hazra, et a1 and, Hazra and Saran had suggested that
oncogenes, oncogene-coded receptors and mitochondria could be profitable targets
for radioimmunotherapy in contrast to shed antigens or non-oncogene-coded surface
target&‘. It was suggested that this would also obviate the problems of antigenic
modulation.
It was also pointed out that in view of the fewer and fewer oncogenes being
recognised  to be of importance, it should be possible to target a large number of
tumours with. a library of a few antibodies directed against the oncogene-coded
proteins. Chan, et al have demonstrated that anti-c-myc oncogene radioimmuno-
targeting has been successful in radioimmunoscintigraphy of lung tumours, although
the possibility that the oncogenes targeted are sited in the tumour cell debris rather
in the cells themselves cannot be ruled out*. The clinical use of antibodies directed
against the EGF receptors has now been reported in brain gliomas as well, where
both radioimmunoscintigraphy and radioimmunotherapy have been achieved’.
4. PANCARCINOMA REACTIVITY
It had always seemed an obstacle that each particular tumour might need a
custom-tailored antibody or a set of antibodies to target it because of endless diversity
of tumour antigens. One solution suggested, as pointed out above, was the use of
antibodies directed against oncogene-coded proteins or receptors. The recent work
from Epstein’s group” indicates another approach where antibodies were directed
against nuclear histone antigens present in the necrotic centres of tumours. Using
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such an antibody to the intracellular insoluble antigen may differentiate rapidly growing
malignant cell tumours with high cell death rate from normal tissues with low cell
death rate. However, such antibodies would also target other necrotic non-malignant
lesions such as myocardial infarction or abscess, etc. However, these relatively
non-specific antihistone antibodies could complement the localization of
tumour-specific antibodies in the better perfused areas of the tumour, thereby,
providing a double-pronged attack on the tumour. A snowball effect has also been
postulated”. The antibody labelled  with the lethal warhead will target turnour  and
kill cells exposing more targets.,
In any case, the interest now being shown in intracellular targets has borne out
the prediction made eight years ago that these were the most profitable targets6y7.
Apart from histones, intracellular fragments such as keratin and nuclear steroid
receptors are also being targeted. We are engaged in an effort to develop antibodies
specific to tumour mitochondria since we believe that with their differential sources
of energy. they are likely to have distinctive antigens. It has also been pointed cnrt
recently that because of their poor rate of repair, the mitochondria of cells are much
more likely to show mutations as compared to the nucleus, and the mitochondrial
DNA fixes mutation 10 to 12 times faster than nuclear DNA. Time alone will tell
whether this approach is going to bear fruit.
5.  INTERNALIZATION OF AN ANTIBODY INTO A TUMOUR
This can be enhanced by the increased permeability of the malignant cells as well
as by selective irradiation7. Matzku from Heidelberg in 1989 found on autoradiography
that antibodies binding to distinct epitopes of an antigen internalize to different degrees
suggesting that one could influence the internalization of the given antibody through
the coordinate action of a companion antibody. The use of external irradiation7,
localized hyperthermia, or lymphokines injected systematically or in the regional
circulation to enhance the permeability of the turnour cell membrane differentially
(i.e., more than that of the normal cell), are other approaches being explored.
6. STRATEGIES FOR ENHANCING SPECIFICITY .
One of the major problems of radioimmunotargeting is non-specific localization
in the reticuloendothelial system, bones and kidneys. Several approaches to this
problem are the subject of research at various centres. Various enhancement strategies
have been devised to improve radioimmunotargeting as shown below:
(a) Radionuclidic-using l”l rather than *Tc for radioimmunoscintigrap;hy.
(b) Radiochemical-using bifunctional chelates and macrocyclic reagents,
spacers, and linkers.
(c) Manipulating the antibody using mouse human chimaera, humanised
antibodies, bispecific antibodies, antibody fragments, and perhaps in the
future, single domain antibodies.
(d) The two-punch approaches in radioimmunotargeting is a phrase that was
used by Hazra, et al” for categorising a set of approaches that involve the
primary injection of anti-tumour antibody followed by a second step in
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which a warhead is conveyed to those targets where after a period of time,
the primary antibody is still present in sufficient quantity while having
cleared from non-specific areas of localization. Such measures include the
use of a heterologous anti-IgG directed against the first antibody to enhance
blood clearance or to convey a warhead; the use of radiolabelled strepavidin
or biotin to link with biotin or avidin on primary antibody. Paganelli13  has
reported the use of 2 mg biotinylated antibody intraperitonealy followed
3 to 5 days later by lOtl-150  fig l”ln-labelled  strepavidin. He has also
described the reverse approach where one mg of the biotinylated antibody
is followed after three days by 4 mg cold avidin and two days later by
200-300  pg of biotin labelled  with ‘i’ln. In the.  latter approach, pure
strepavidin is not required. The former approach was suitable for
intraperitoneal regional localization of the tumour whereas the latter
method was suitable for intravenous systemic administration. Other
approaches are the use of radiolabelled protein A and the use of
a bifunctional antibodyone arm of which looks at a tumour antigen while
the other arm looks at a warhead transporting molecule. Somewhat
analogous to this two-punch approach is the use of boron-labelled primary
antibodies which are later irradiated by thermal neutrons for local
conversion into lithium and release of alpha particles.
(e) Manipulating the tumour by irradiation or lymphokines or increasing
vasculkity .
Nardo (personal communication) has pointed out that the use of linkers between
the antibody and the chelate, which are subjected to intracellular attacks by enzymes
in hepatocytes, can release the chelates so that non-specific reticula-endothelial  system
hepatic accumulation is reduced. Paik14 has described how, using labelled  disulphide
and diester linkages between the antibody and “‘1~DTPA,  it was possible to enhance
the target to blood ratio by a factor of 15. This may  also be important  in the  visualization
of hepatic metastasis of a tumour where the specific localization of the .antibody in
the metastatic lesion must be differentiated from non-specific localization in the normal
liver. The disulphide linkage is easily metabolised by the healthy liver. The diester
linkage is similarly easily metabolised in the kidney and this could be of value in
reducing the kidney activity of “‘ln-labelled  Fab fragments.
In order to reduce the bone localization the same group has described the use
of macrocyclic chelating agents such as pbromoacetamidobenzyl-DOTA  (BAD)
whose capacity to stably link to 9oY is far greater than that of older bifunctional
chelates such as DTPA cyclic anhydride. 12- and 1Cmembered  rings have been
developed for this purpose. 2-imidothalene is used as a spacer between the antibody
and the chelate.
In order to prepare a radiopharmaceutical free of non-specificity bound yttrium,
the BAD xw,Y  chelate is prepared, separated from unchelated yttrium and then
conjugated with the antibody instead of using the pharmaceutical prepared by
conjugating BAD with the antibody and then post-labelling with the radiometal. The
spacer permits labelling avoiding steric hindrance.
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7. ISOTOPIC VS NON-ISOTOPIC TUMOUR IMAGING
Eckelman has,listed the advantage of radio-labelled antibodies over CT and NMR
modalities of tumour imaging”. With radiopharmaceuticals, the concentration of the
image enhancing agent is less than 0.1 p mole/kilo while the figures for iodinated and
paramagnetic contrasts are lOOO-10,000 and 10-1000 p mole/kilo respectively. Since
the latter two need contrast agents at relatively high concentrations, they are ‘not’
suited for measuring tissue perfusion changes and specially not well suited for
measuring biochemical processes: Despite the poor resolution of planar gamma
cameras as compared to CT and’ NMR, useful images can be obtained as it measures
the changes in tissue perfusion or biochemical parameters. Isotopic diagnosis is also
superior for whole body survey for extensive metastases, for predicting distribution
of the subsequent therapeutic dose of the antibody and for staging and monitoring of
therapeutic response.
SPECT studies have higher resolution than planar gamma camera but it requires
5-10  per cent of the injected dose in the target organ which is a far cry from 0.1 per
cent antibody localization currently achieved.
8. TECHNETIUM’S COMEBACK FOR RADIOLABELLING ANTIBODIES
About a decade ago it was considered difficult to label antibodies stably with
wmTc and therefore ‘231-labelied
radioimmunoscintigraphy. However, ‘23
antibodies came into use for
lis only’available from high energy cyclotrons,
and therefore is not a very practical agent for many centres as compared to wmTc
available everywhere from generators. 13i1 is not very  suitable for
radioimmunoscintigraphy as contrasted to therapy. Better methods for making
99mTc-labelled antibodies have now been developed. The Schwarz  technique describes
the method of protein modification by reducing with a thiol reagent (Zmercaptoethanol
or 2-aminoethanethiol  hydrochloride) which essentially facilitates 99mTclabelling  using
a standard bone imaging kit, and provides radiolabelled monoclonal antibody suitable
for routine clinical use’6. The approach has been adopted by Granowska, eta1 (London)
using PRIA3  antibody for imaging coldrectal carcinoma. The identification of tumour
deposits as early as 4 hours after injection ,confirms  the viability of early imaging with
99m Tc,  product. Similarly, wmTc  labelling has been used with BW431/26  monoclonal
intibody  for imaging liver metastases from. colorectal cancer (Gottingen), BW575/9
for neuroblatoma (Frankfurt), BW494/32  for small bowel and ovarian tumours
(Aachen) and 225.285 for imaging melanoma (Leiden). Clearly, the availability- of
technetium antibodies will open up immunoscintigraphy to the majority of nuclear
medicine departments. D.M. Goldenberg (CMMI, Newark, USA) has reported his
initial clinical results with a new *Tc antibody kit developed by Immunomedics, Inc.
(Warren, USA) which is a one vial, one step, five-minute labelling method that
involves direct conjugation of the radionuclide to the Fab segment of the antibody
achieving planner and SPECT imaging of tumour within two to five hours without
background radioactivity being present, and lesions as small as 3 mm were revealed17.
The following are the three general approaches now available for linking
technetium to antibodies:
(a) Direct labelling using the aminoacids of IgG to complex technetium. Such
labelling was earlier reported to be weak and unstable. High affinity
labelling is dependent on the reduced disulphide groups which can be
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achieved in the presence of reducing agents such as stannous ions, and
more recently sodium dithionite and ascorbic acid. The latter appears to
be the most promising‘*. Low affinity binding of 9s”‘Tc  to other sites of
antibody can be prevented by the presence of excess of DTPA, and
therefore it has been suggested that direct radiolabelling of %Tc on the
immunoglobulin should always be done in the presence of DTPA so that
there is no loosely bound 99mT~.
(b) The second approach involves the use of bifunctional chelates linking the
protein to the radiometal. Unfortunately there can be a competition
between binding of the 99mT~  by the covalently bound chelating agents
and the strong or weak direct reaction of the 99mT~  with the antibody. It
is therefore difficult to achieve high radiochemical purity.
(c) In the pre-labelled ligands-approach, the bifunctional chelate is first
labelled  with the radiometal and later the pre-labelled ligand is bound with
the antibody. This eliminates any direct labelling of the protein by the
99mTc.  This yields the most stable bonds, but only 4 per cent of the %Tc
bonds to IgG.  The pre-labelled ligand approach thus reduces the chances
of wmTc  leaching off from target homed antibody which would have
enhanced background.
The strong direct binding and also some chelation methods are dependent on the
presence of sulphydryl (SH) groups. A number of methods have been described using
2-iminothiolate to introduce a SHgroup  in chelates or in the antibody for this purpose.
9. NEWER RADIOISOTOPES AS CANDIDATE RADIONUCLIDES FOR THERAPY
The oldest workhorse for radioisotopic therapy in thyroid carcinoma has been
1311  and I remember being fascinated by Brig. Mazumdar dispensing therapy doses.
In ‘view of the ease of incorporating iodine in antibodies, 1311  was used for
radioimmunotherapy ‘as well. However, I311 has several disadvantages-notably its
gamma radiation which contributes to whole body dose and non-target dose. Several
other isotopes are therefore under investigation in the West for radioimmuotherapy,
notably WY and ‘53Sm.  Ganso (NDI, Bethesda, USA) has been looking at the use of
bismuth and lead. Apart from these beta emitters, the alpha emitter “‘At  has also
attracted attention. Unfortunately many of these isotopes are unsuitable in our opinion
for radioimmunotherapy. A list of candidate radionuclides for radioimmunotherapy
has been prepared and classified according to half-life, and suitability for use in India
(Tables 1 and 2).
Since the accumulation of antibody in the tumour takes a finite time of the order
of three days, short-lived isotopes such as bismuth are of no value. We feel that
radionuclides produced from the same isotopes cannot be carrier-free and would
therefore pose problems in linking to chelates. However, despite these problems,
lR8Re and ‘53Srn  are being advocated in certain western centres as the specific activity
obtained is high enough to confer the desired dose.
For therapy in India, there are additional problems because of non-availability
of a cyclotron for medical pruposes, and the large distances between the production
facility and the potential users throughout the country. Hazra, et al therefore
considered radiogold and radiosilver as being particularly suitable for our country”.
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Half-life
Less than
24 hrs
24 to 48 hrs
Table  1. C
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gamma toxic short state
TV2
=Br 9oY 99Mo
gRu ‘09Pd  “‘Cd
117msn 121sn  MO&$
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~Y’%Jl
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laTe nA.9  ‘wP$j 2’2Bj 2”At
19’Au lnSb
‘IlAg  was prepared from iioPd by n-gamma process and ‘separated by Dowex anion
exchange chromatography to yield a carrier-free product. lwAu  was similarly prepared
from 19’Pt  and purified by solvent extraction. Incorporation of ‘llAg in monoclonal
antibodies poses problems as it is monovalent and therefore not suitable for
conventional bifunctional chelates. Certain cryptate (crown ethers) macrocyclic agents
have been suggested for monovalent cations. Certain other hetero-bifunctional agents
such as para-aminobenzoic  acid (PABA) and -N-succinimidyl  3-(2-pyridyldithio)
propionate (SPDP) are being explored for this linkage utilising the affinity of silver
for sulphur, this being a soft-base-soft-acid interaction. Methods for the stable linkage
of gold to immunoglobulin are available for in vitro use and their adaptation for in
tivo purposes is under study.
In June 1990,  Srivastava from Brookhaven has presented a poster at the Princeton
Radiopharmaceutical Meeting displaying great interest in radiogold and its preparation
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from platinum. He has also suggested the creation of the gold adduct of II gold atoms
for linkage to antibodies. If this succeeds, a very large dose can be delivered per
antibody molecule.
10. CONCLUSION
A birds eye view of several new facets in the exciting area of radioimmunotargeting
has been provided in this paper. It is clear that the problems are great and the path
is strewn with obstacles, but the sun of successful radioimmunotherapy for carcinoma
is glimmering on the horizon.
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